MedTrace Logo

BIOmarkers of Dyspnea IN Emergency Room

NCT01227317 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 444

Last updated 2011-12-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine vasopressin), Pro endothelin to stratify the risk in severe dyspnea.

Conditions

Interventions

OTHER

Prognostic value of Biomarkers

Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients

Sponsors & Collaborators

  • ThermoFisher Scientific Brahms Biomarkers France

    lead INDUSTRY

Principal Investigators

  • Pierre Hausfater, Pr · ED Pitié SalpêtrièreHospital in Paris

  • Yann-Erick Claessens, Dr · ED Cochin Hospital in Paris

  • Guillaume Der Sahakian, Dr · ED Hotel Dieu Hospital in Paris

  • Arnaud Martinage, Dr · ED Hotel Dieu Hospital in Nantes

  • Fatima Rayeh, Dr · ED La Miletrie Hospital in Poitiers

  • Eric Weil, Pr · ED Hospital B in Lille

  • Luc-Marie JOLY, Dr · ED Charles Nicolle Hospital in Rouen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-08-31
Completion
2011-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01227317 on ClinicalTrials.gov